Document Detail


Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis.
MedLine Citation:
PMID:  19189055     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Cerebral radiation necrosis is a serious complication of radiation treatment for brain tumors. Therapeutic options include corticosteroids, anticoagulation and hyperbaric oxygen with limited efficacy. Bevacizumab, an antibody against VEGF had been reported to reduce edema in patients with suspected radiation necrosis. We retrospectively reviewed 6 patients with biopsy proven cerebral radiation necrosis treated with bevacizumab between 2006 and 2008.
RESULTS: Interval MRI follow-up demonstrated radiographic response in all patients with an average reduction of 79% for the post gadolinium studies and 49% for the FLAIR images. The initial partial radiographic response was noted for up to a mean follow-up time of 5.9 months (6 weeks to 18 months).
CONCLUSION: Bevacizumab appears to produce radiographic response and clinical benefits in the treatment of patients with cerebral radionecrosis.
Authors:
Roy Torcuator; Richard Zuniga; Yedathore S Mohan; Jack Rock; Thomas Doyle; Joseph Anderson; Jorge Gutierrez; Samuel Ryu; Rajan Jain; Mark Rosenblum; Tom Mikkelsen
Related Documents :
19558065 - Single burr hole drainage for chronic subdural haematoma.
2701035 - Relief of epilepsy by radiosurgery of cerebral arteriovenous malformations.
12296635 - Prediction of death in patients with primary intracerebral hemorrhage: a prospective st...
23835715 - Obinutuzumab (ga101) in patients with relapsed/refractory indolent non-hodgkin lymphoma...
21830115 - Muscle activity around the knee and gait performance in unicompartmental knee arthropla...
17458395 - Treatment of ankylosing spondylitis with moxifloxacin.
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2009-02-03
Journal Detail:
Title:  Journal of neuro-oncology     Volume:  94     ISSN:  1573-7373     ISO Abbreviation:  J. Neurooncol.     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-07-06     Completed Date:  2009-10-01     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  8309335     Medline TA:  J Neurooncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  63-8     Citation Subset:  IM    
Affiliation:
Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, 2799 W Grand Blvd, Detroit, MI 48202, USA. nsroy@neuro.hfh.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Biopsy / methods
Brain Diseases / drug therapy*,  pathology*
Brain Neoplasms / radiotherapy
Female
Glioblastoma / radiotherapy
Humans
Magnetic Resonance Imaging / methods
Male
Middle Aged
Necrosis / diagnosis,  drug therapy*,  etiology
Radiation Injuries / drug therapy
Radiotherapy / adverse effects
Retrospective Studies
Tomography Scanners, X-Ray Computed
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A metabolically stable analogue of anandamide, Met-F-AEA, inhibits human thyroid carcinoma cell line...
Next Document:  Effect of lactoferrin on oxidative features of ceruloplasmin.